

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
BOOKLET LABEL ON PACK FOR 1x1 dose, 10x1 doses, 25x1 doses or 100x1
doses

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vanguard CPV suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 1 ml dose contains:

Canine parvovirus, strain NL-35-D, live, low passage, minimum: $10^{7.0}$ CCID₅₀*.

*Cell culture infectious dose 50%

Contains traces of neomycin and gentamycin.

3. PACKAGE SIZE

25 x 1 ml

1 x 1 ml

10 x 1 ml

100 x 1 ml

4. TARGET SPECIES

Dogs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.

Do not freeze.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium S.A.

14. MARKETING AUTHORISATION NUMBERS

Vm 60021/3026

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS
VIAL, 1 DOSE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vanguard CPV

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Canine parvovirus, strain NL-35-D, live, low passage, minimum: $10^{7.0}$ CCID₅₀.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Vanguard CPV suspension for injection

2. Composition

Each 1 ml dose contains:

Active substance:

Canine parvovirus, strain NL-35-D, live, low passage, minimum: $10^{7.0}$ CCID₅₀*.

*Cell culture infectious dose 50%.

Excipients:

Neomycin

Gentamycin

Clear to slightly turbid reddish liquid.

3. Target species

Dogs

4. Indications for use

For the active immunisation of dogs to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), and to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c).

Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Schedule. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.

Duration of immunity: 12 months.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

The canine parvovirus vaccinal strain may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this

strain, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.

High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA against CPV are present, this should be taken into account when planning the timing of vaccinations.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice and show the package leaflet or the label to the physician.

Pregnancy:

Do not use during pregnancy.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except when used with vaccines from the Vanguard range containing canine distemper virus, canine adenovirus, canine parainfluenza virus or leptospira antigens. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

Overdose:

No reaction other than those listed in section on Adverse events are observed after administration of a 10-fold overdose.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Dogs.

Common (1 to 10 animals / 100 animals treated):
Injection site swelling ¹
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Anaphylaxis (e.g. vomiting) ²

¹ Transient. May occur 4-6 hours after vaccination, resolves after approximately 7 days.

² If such reaction occurs, administer adrenaline or an equivalent.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

E-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously.

Basic Vaccination Schedule:

Puppies younger than 10 weeks of age:

Two doses of Vanguard CPV at least 14 days apart. The first dose can be given as young as 6 weeks of age. The second dose should not be given until at least 10 weeks of age.

Puppies 10 weeks of age and older:

A single dose of Vanguard CPV, followed by a single dose of Vanguard Lepto ci at least 14 days later.

Re-vaccination Schedule:

A single dose of Vanguard CPV to be given annually thereafter.

See Other Information section for more detailed guidance relating to duration of immunity.

9. Advice on correct administration

Shake well before use.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBER AND PACK SIZES

Vm 60021/3026

Pack contains 1, 10, 25 or 100 vials of 1 ml of Vanguard CPV.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis Belgium S.A.
2nd Floor, Building 10
Cherrywood Business Park
Loughlinstown
Dublin 18
D18 T3Y1
Ireland
Tel: +353 (0) 1 256 9800

Manufacturer responsible for batch release:

Zoetis Belgium
Rue Laid Burniat 1
1348 Louvain-La-Neuve
Belgium

17. Other information

Annual booster vaccination is recommended. However, should Veterinary Surgeons conduct a risk-benefit analysis for individual animals to determine the frequency of revaccination with Vanguard CPV, they should be aware of the following information. Serological data has indicated that most dogs, when given at least the first annual booster, can maintain protective levels of immunity to the parvovirus component of Vanguard CPV for up to 4 years. For further information please contact the company. Canine parvovirus disease in kennels and pet shops is a problem of intensive husbandry and must be treated as such. Without careful professional attention to management practices in such places, successful disease control may be difficult to achieve.

When used in accordance with the recommended vaccination regime, Vanguard CPV can aid in the reduction of environmental contamination of canine parvovirus.

POM-V

Gavin Hall

Approved: 19 December 2025